Infectious Disease & Vaccines

CRISPR biosensing technology provides unambiguous pathogen detection.

Automated synthetic biology workflows enable efficient mRNA-based therapeutic development.

Using comedy to talk about technical topics makes science more accessible.

What do 23andMe and Snapchat have in common? They both collect very personal information about their users. Do the benefits outweigh the risks?

Antibiotic resistance is on the rise and scientists are on the lookout for new therapeutics for treating human pathogens. One promising new venture repurposes antimalarial drugs to treat patients with chronic lung diseases such as cystic fibrosis.

Join a panel of experts as they discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery.  

Armed with a machine learning and systems biology approach, John Tsang studies how past infections and vaccinations shape an individual’s immune response to future vaccines.

People with COVID-19 sometimes lose their sense of smell. But a clinical researcher has a possible solution: the patient’s own blood.

Anna Blakney, an RNA bioengineer and TikTok science communicator, studies how self-amplifying RNA improves RNA vaccines and therapeutics.

It’s human nature to compare one’s success to others, but thinking that the grass is greener on the other side can be detrimental to one’s health. Recognizing strategies as equal but unique ways to tackle a common problem is a healthier perspective.

A once fringe theory that viral and bacterial infections trigger the neuroinflammation and cognitive decline associated with Alzheimer’s disease is gaining traction. If it proves true, available antimicrobials could be a long sought-after treatment for this neurodegenerative disease.

Pre-screening of the gut microbiome may lead to a more personalized approach to treating intestinal parasitic worm infections, leading to better treatment outcomes and a decreased risk for drug resistance.